Oligonucleotide-based therapeutics are rapidly gaining traction in the biopharmaceutical industry, with over 20 FDA- and EMA-approved drugs and many more in development. These innovative treatments target diseases at the genetic level, offering precise therapeutic interventions that were previously impossible. However, their complexity presents significant analytical challenges, requiring rigorous structural characterization and impurity profiling.
This blog explores the key considerations in oligonucleotide analysis, the regulatory expectations, and the advanced analytical techniques that ensure product quality and safety.
Modern drug design enables the development of highly tailored oligonucleotide therapeutics with enhanced stability, activity, and targeting capabilities. Through sophisticated chemical synthesis, researchers can incorporate specific structural modifications that improve drug performance. However, these modifications add complexity to structural characterization, demanding robust analytical strategies.
Regulatory agencies, including the FDA and EMA, require comprehensive structural analysis to confirm that the intended product has been synthesized correctly and to assess any associated impurities. So, what are the critical considerations for analyzing these complex molecules?
Both the FDA and EMA have published guidance documents outlining the requirements for oligonucleotide analysis. Additionally, the FDA provides product-specific guidance for certain oligonucleotide therapeutics, detailing comparative structural analysis requirements. These regulations emphasize the need for a thorough characterization of both the drug product and any impurities present.
For confirming the primary sequence and detecting structural modifications, mass spectrometry (MS) is a critical tool. Its high mass accuracy and ability to generate detailed fragment ion data allow for precise nucleotide sequencing. Unlike enzymatic digestion methods, which may be ineffective against chemically modified oligonucleotides (e.g., phosphorothioate linkages, base modifications, and PMOs), MS provides a reliable, high-resolution approach to structural verification.
Beyond primary sequence analysis, assessing higher-order structures is essential. Nuclear Magnetic Resonance (NMR) spectroscopy plays a pivotal role in this aspect, with techniques such as:
Emerging technologies, such as microfluidic modulation spectroscopy (MMS, e.g. Aurora TX), further enhance secondary structure investigations, including thermal stability assessments. Additional orthogonal techniques like Circular Dichroism (CD) and Fourier-Transform Infrared Spectroscopy (FT-IR) provide complementary data, strengthening structural understanding.
Chemical synthesis is rarely 100% efficient, leading to a variety of potential impurities, including:
These impurities must be thoroughly investigated, as outlined in regulatory guidelines. Advanced liquid chromatography techniques, combined with mass spectrometric analysis, provide deep insights into impurity profiles. Additionally, ion mobility spectrometry (IMS) enables the separation and characterization of enantiomeric oligonucleotide species, offering a powerful tool for in-depth impurity assessment.
Beyond product-specific impurities, contaminants may also arise from the manufacturing process itself. These include residual solvents from chemical synthesis and elemental impurities introduced through raw materials
Regulatory frameworks, including ICH guidelines (Q3A, Q3B, Q3C, and Q3D), mandate the assessment or risk evaluation of these impurities. Gas Chromatography-Mass Spectrometry (GC-MS) effectively detects residual solvents, while Inductively Coupled Plasma Mass Spectrometry (ICP-MS) is the gold standard for elemental impurity analysis.
Design effective structural characterization studies for oligonucleotide therapeutics.
Example data from the analysis of unmodified Inotersen and Inotersen.
Oligonucleotide therapeutics represent a groundbreaking advancement in medicine, offering new treatment possibilities for previously untreatable conditions. However, ensuring their quality, efficacy, and safety requires a sophisticated and multi-faceted analytical approach.
By leveraging cutting-edge techniques such as mass spectrometry, NMR, chromatography, and other emerging structural analysis technologies, researchers can achieve the deep molecular insights needed to optimize manufacturing and regulatory compliance. Comparative studies with innovator products can further support analytical assessments, ensuring that new oligonucleotide therapies meet the highest standards of quality.
As the field continues to evolve, staying at the forefront of analytical advancements will be essential for driving the success of oligonucleotide-based drugs.
How can we help accelerate the development of your oligonucleotide therapeutic?
